UCLA researchers have identified a way to make antibody-drug conjugates more powerful against metastatic castration-resistant prostate cancer, an advanced form of the disease that continues to resist many treatments. In laboratory experiments and mouse models, the investigators found that combining these targeted therapies with a drug that blocks the survival protein BCL-XL produced substantially more cancer cell death and slowed tumor growth more effectively than either treatment alone. The findings suggest that redesigning how antibody-drug conjugates attack prostate tumors could help overcome one of the most persistent challenges in treating the disease.
Metastatic castration-resistant prostate cancer develops when prostate tumors continue to grow and spread despite therapies that suppress male hormones, which normally fuel prostate cancer progression. Although newer hormonal medicines, chemotherapy drugs and radiopharmaceuticals have improved care, the disease remains incurable once it reaches this stage. Antibody-drug conjugates, or ADCs, have revolutionized treatment for some breast, bladder and blood cancers, yet their effects in advanced prostate cancer have generally been modest and short-lived. UCLA scientists set out to determine whether existing ADC strategies could be made more effective without having to create an entirely new class of therapy.
An ADC is a molecular delivery system that links three components: an antibody, a chemical linker and a highly potent drug payload. The antibody recognizes a protein displayed on the surface of cancer cells, allowing the conjugate to bind to the tumor. After the cancer cell internalizes the ADC, the linker is broken down or chemically cleaved, releasing the payload inside the cell. This design concentrates a powerful cytotoxic drug where it is needed while potentially reducing exposure to healthy tissues. However, the approach can fail when tumors do not express enough of the target, rapidly repair the damage caused by the payload or activate survival mechanisms that prevent cell death.
The UCLA-led team first examined tumor samples from patients with advanced prostate cancer to understand whether multiple targets could be exploited at the same time. Their analysis showed that B7-H3, PSMA and STEAP1—three proteins already being investigated as targets for ADCs—were frequently present on the same cancer cells. This pattern is important because it suggests that different ADCs might be used in combination, or engineered to recognize multiple tumor-associated proteins, increasing the likelihood that cancer cells will be reached. At the same time, targeting proteins that are more abundant on tumor cells than on normal tissue could help maintain the precision that makes ADCs attractive.
The researchers then tested dozens of combinations involving payloads commonly used in ADC development. They were looking for drug pairs that produced synergy, meaning the combined effect was greater than would be expected from simply adding the activity of each drug individually. One combination consistently stood out: a DNA-damaging payload paired with a compound that inhibits BCL-XL. DNA-damaging agents can create breaks or lesions in the genetic material of cancer cells, but those cells may survive by activating molecular repair and stress-response pathways. BCL-XL acts as one of the proteins that helps prevent programmed cell death, or apoptosis, allowing damaged cells to remain alive.
Blocking BCL-XL appears to remove an important escape route. When prostate cancer cells were exposed to DNA damage while this survival protein was inhibited, they were less able to withstand the treatment and more likely to undergo apoptosis. In cell cultures, the combination caused significantly greater cancer cell death than either the DNA-damaging drug or the BCL-XL inhibitor alone. The same pattern emerged in mice implanted with advanced prostate tumors: combination treatment reduced tumor growth more strongly than single-agent therapy, supporting the idea that the two mechanisms reinforce one another inside the cancer cell.
The study also identified a possible genetic clue that could help determine which patients might benefit most. Tumors retaining an intact TP53 tumor suppressor gene responded particularly well to the treatment strategy. TP53 encodes the p53 protein, a central regulator of cellular stress responses that can halt cell division or promote apoptosis when DNA becomes severely damaged. Many cancers disable this protective system through TP53 mutations, potentially changing how they respond to DNA-damaging therapies. The researchers’ findings suggest that TP53 status may eventually become part of a biomarker strategy for selecting patients for ADC combinations, although this possibility must be tested prospectively in clinical trials.
The results also point to a broader principle in ADC design: the payload may be just as important as the target. Rather than treating an ADC as a fixed package consisting of one antibody and one chemotherapy drug, researchers can potentially match different payloads to the vulnerabilities of particular tumor types. In prostate cancer, pairing a DNA-damaging agent with a BCL-XL inhibitor may be especially effective because it attacks both the tumor’s genetic material and its ability to survive the resulting stress. Combining ADCs that recognize B7-H3, PSMA or STEAP1 could add another layer of pressure by increasing tumor-cell coverage.
The findings remain preclinical, and the treatment has not yet been shown to benefit patients. BCL-XL is also involved in the survival of some normal cells, meaning that safety, dosing and the management of possible side effects will be critical as the strategy moves toward human testing. The UCLA team is now engineering next-generation ADCs that incorporate the most promising payload combinations and evaluating additional ways to target prostate cancer cells. If these experiments are validated in clinical studies, the approach could transform ADCs from short-lived treatments into more durable, biologically tailored therapies for men with metastatic castration-resistant prostate cancer.
Subject of Research: Antibody-drug conjugate combinations targeting metastatic castration-resistant prostate cancer.
Web References: Journal of Clinical Investigation study; DOI link; UCLA Health Jonsson Comprehensive Cancer Center.
References: Semenova G. et al., Journal of Clinical Investigation, DOI: 10.1172/JCI200438.
Keywords: prostate cancer, metastatic castration-resistant prostate cancer, antibody-drug conjugates, ADCs, BCL-XL, PSMA, B7-H3, STEAP1, TP53, targeted cancer therapy, combination therapy, precision oncology.
